Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Debt (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Debt for 4 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed 0.17% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, changed 0.17% year-over-year, with the annual reading at $14.3 million for FY2025, 0.17% changed from the prior year.
  • Non-Current Debt for Q4 2025 was $14.3 million at Orchestra BioMed Holdings, roughly flat from $14.2 million in the prior quarter.
  • The five-year high for Non-Current Debt was $14.4 million in Q2 2025, with the low at $9.5 million in Q4 2022.
  • Average Non-Current Debt over 4 years is $12.5 million, with a median of $14.2 million recorded in 2025.
  • Peak annual rise in Non-Current Debt hit 0.17% in 2025, while the deepest fall reached 0.17% in 2025.
  • Over 4 years, Non-Current Debt stood at $9.5 million in 2022, then grew by 0.77% to $9.6 million in 2023, then soared by 49.45% to $14.3 million in 2024, then decreased by 0.17% to $14.3 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $14.3 million, $14.2 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.